source
- Jazz Pharmaceuticals to acquire Actio Biosciences in deal worth over $1.3 billionJazz Pharmaceuticals announced an agreement to purchase Actio Biosciences, a San Diego biotech focused on genetic epilepsies. The transaction could total just over $1.3 billion, with $820 million…
- Sionna's CF add-on pill fails to improve outcomes in Phase 2 trial with TrikaftaSionna Therapeutics reported that its experimental cystic fibrosis pill, SION-719, did not provide any additional benefit when combined with Vertex Pharmaceuticals' Trikafta in a Phase 2 study. Th…